About Ocean Biomedical, Inc.
http://www.oceanbiomedical.comOcean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation.
CEO
Inderjote Kathuria
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public November 8, 2021
Method of going public IPO
Full time employees 7
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
BLACKROCK INC.
Shares:99.88K
Value:$69.92
COHEN & CO FINANCIAL MANAGEMENT, LLC
Shares:59.72K
Value:$41.8
AYRTON CAPITAL LLC
Shares:13.35K
Value:$9.34
Summary
% Of Shares Owned 0.07%
Total Number Of Holders 4
Showing Top 3 of 4
Market Cap $237271
52w High $0.66
52w Low $0.00
P/E 0
Volume 7.78K
Outstanding Shares 232.37M
About Ocean Biomedical, Inc.
http://www.oceanbiomedical.comOcean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2025 | $0 | $958K ▼ | $-8.24M ▼ | 0% | $-0.3 ▼ | $-7.9M ▼ |
| Q4-2024 | $0 | $1.75M ▲ | $283K ▲ | 0% | $0.01 ▲ | $716K ▲ |
| Q3-2024 | $0 | $768K ▲ | $-5.53M ▲ | 0% | $-0.2 ▲ | $-5.07M ▲ |
| Q2-2024 | $0 | $682K ▲ | $-17.23M ▼ | 0% | $-0.63 ▼ | $-16.72M ▼ |
| Q1-2024 | $0 | $595K | $13M | 0% | $0.48 | $13.64M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2025 | $0 | $1.58M ▲ | $93.98M ▼ | $-92.4M ▲ |
| Q4-2024 | $0 | $902K ▼ | $98.52M ▼ | $-97.62M ▲ |
| Q3-2024 | $0 ▼ | $1.13M ▼ | $99.22M ▲ | $-98.08M ▼ |
| Q2-2024 | $4K ▼ | $1.85M ▼ | $94.59M ▲ | $-92.74M ▼ |
| Q1-2024 | $19K | $2.95M | $78.73M | $-75.78M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2025 | $-8.24M ▼ | $-356K ▲ | $0 | $909K ▼ | $553K ▲ | $-356K ▲ |
| Q4-2024 | $283K ▲ | $-2.52M ▼ | $0 | $2.5M ▲ | $-16K ▼ | $-2.52M ▼ |
| Q3-2024 | $-5.53M ▲ | $-885K ▼ | $0 | $896K ▲ | $11K ▲ | $-885K ▼ |
| Q2-2024 | $-17.23M ▼ | $-290K ▲ | $0 | $0 | $-290K ▲ | $-290K ▲ |
| Q1-2024 | $13M | $-485K | $0 | $0 | $-485K | $-485K |
CEO
Inderjote Kathuria
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public November 8, 2021
Method of going public IPO
Full time employees 7
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
BLACKROCK INC.
Shares:99.88K
Value:$69.92
COHEN & CO FINANCIAL MANAGEMENT, LLC
Shares:59.72K
Value:$41.8
AYRTON CAPITAL LLC
Shares:13.35K
Value:$9.34
Summary
% Of Shares Owned 0.07%
Total Number Of Holders 4
Showing Top 3 of 4